CA
NZ
UK
AU
IND
US
Amphastar Pharmaceuticals (NASDAQ:AMPH) shares closed higher today, extending a strong run over the past six months that has outpaced the broader market. Second-quarter results showed earnings per share of $0.91 versus a $0.62 estimate, with revenue of $183.9 million above consensus, reinforcing the company's …
BillionToOne (NASDAQ:BLLN) shares closed sharply higher today, extending a multi-week rally driven by favorable Medicare reimbursement developments. Preliminary 2027 CMS lab fee schedule data showed oncology test rates rising 29% and UNITY Fetal Risk prenatal reimbursement jumping 112%, with management characterizing the net impact …
Acadia Pharmaceuticals (NASDAQ:ACAD) shares closed sharply lower today after the company reported topline results from the Phase 2 portion of its RADIANT trial evaluating remlifanserin for Alzheimer's disease psychosis. The 60 mg once-daily dose narrowly missed the primary endpoint of change in hallucination and …
Adaptive Biotechnologies (NASDAQ:ADPT) shares closed at fresh 52-week highs today, extending a strong multi-week run driven by improving fundamentals and bullish analyst commentary around its clonoSEQ minimal residual disease testing franchise. The rally follows the company's second-quarter report showing 22% overall revenue growth and …
Agilon Health (NYSE:AGL) shares plunged today, sharply underperforming both the healthcare sector and the broader market, which were only modestly lower in a session marked by a macro backdrop of surging Treasury yields, with the 10-year near 5.1%, and rising oil prices. The sell-off …
Abbott Laboratories (NYSE:ABT) shares closed lower today alongside broader weakness across the medical device and healthcare sector, after the Centers forMedicareand Medicaid Services announced it would cancel Affordable Care Act coverage for roughly 760,000 people and claw back billions of dollars in subsidies. The …
Absci (NASDAQ:ABSI) shares closed higher today after the company announced additional details for its planned Phase 2 STORYLINE clinical trial evaluating ABS-201, an investigational anti-prolactin receptor antibody engineered with the company's generative AI platform, for endometriosis. The planned double-blind, placebo-controlled trial would assess efficacy …
The latest price action, however, reflects a period ofconsolidation near elevated levelsrather than another immediate breakout. After rallying sharply from the$125–$130 area during June and July, MRK accelerated higher through August and briefly pushed toward the$155–$157 region. The subsequent pullback and sideways movement have …
Today's session delivered continuation of an aggressive multi-week breakout for Moderna, Inc. (NASDAQ: MRNA), with buyers driving the tape to fresh multi-year cycle highs near $189.00 before consolidating constructively. Following a transformative high-volume gap-up in mid-August 2026, the pioneer in messenger RNA therapeutics and …
BullFrog AI Holdings, Inc. shares began climbing Tuesday, September 22, 2026, closing up 21.70 percent at USD 0.60 after SEC filings disclosed that CEO Vininder Singh had purchased 75,000 shares at a weighted-average price of USD 0.5989, a transaction worth roughly USD 44,918, while …
Please wait processing your request...